Gal-3参与阿尔茨海默病的机制研究进展  

Research progress on the role of Gal-3 in Alzheimer′s disease

作　　者：万琪 谢晔 王蓉 骆延 曾俊伟 WAN Qi;XIE Ye;WANG Rong;LUO Yan;ZENG Junwei(Department of Physiology,Zunyi Medical University,Zunyi 563000,China)

机构地区：[1]遵义医科大学生理学教研室,563000

出　　处：《天津医药》2022年第10期1115-1120,共6页Tianjin Medical Journal

基　　金：国家自然科学基金资助项目(31860291);贵州省教育厅创新群体重大研究项目(黔教合KY字[2018]025)。

摘　　要：半乳糖凝集素-3(Gal-3)属半乳糖苷凝集素家族,表达于神经系统,可结合多种分子,通过调节下游信号发挥作用。在阿尔茨海默病(AD)患者的病变脑区、血清和脑脊液中,Gal-3的表达变化与AD病变进程相关。因此,Gal-3有望成为AD诊断与检测药物疗效的重要生物标志物。该文就Gal-3参与AD的分子机制研究进展进行综述,以期为AD的诊断、治疗及药物研发提供新观点。Galectin-3(Gal-3),widely expressed in central nervous system,is a member of the galectin family.Gal-3 can bind a variety of molecules and play a role by regulating downstream signals.Recent advances have suggested that changes in Gal-3 expression in brain tissues,serum and cerebrospinal fluid of patients with Alzheimer′s disease(AD)are closely related to the severity of AD.Therefore,GAL-3 is expected to be an important biomarker for the diagnosis and detection of drug efficacy in AD.In this review,we present an updated overview of the current understanding of Gal-3 involvement in AD,which may provide useful references for the clinical diagnosis and treatment of AD in the future.

关 键 词：阿尔茨海默病 半乳糖凝集素3 炎症 淀粉样β肽类 小神经胶质细胞 

分 类 号：R338.2[医药卫生—人体生理学]